The introduction of targeted therapies, such as BRAF (vemurafenib and dabrafenib) and MEK (trametinib and cobimetinib) inhibitors, as single agents or in combination [1,2], led to both improved response rates and mean overall survival of metastatic melanoma patients bearing the BRAFV600E mutation or mutant NRAS [3,8]. The gene discussed is BRAF; the disease is metastatic melanoma.